Continuous biomarker monitoring does more harm than good for patient health

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Machine-learning models integrating early antibody signatures discriminated individuals who would later develop Crohn's disease or ulcerative colitis from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively.

Study co-author Dr. You Zhou stated that combining gut bacteria and digestive chemicals distinguished individuals with mild cognitive impairment from healthy people with high accuracy.

Researchers from Cardiff University and Imperial College London found that older adults with mild cognitive impairment displayed significantly elevated levels of Izemoplasmatales spp. bacteria and the chemical proline in fecal samples.

The study utilized machine learning algorithms to analyze fecal sample biomarkers to diagnose mild cognitive impairment and predict condition progression speed.

Researchers profiled antibody responses against approximately 357,000 antigens across 2,000 serum samples, identifying 123,980 unique antibodies and finding significantly lower antibody diversity in individuals who later developed Crohn's disease or ulcerative colitis.

More young people need to get their brain scanned

Dr. Aasma Shaukat stated at the ACG Annual Scientific Meeting that researchers plan to develop future iterations beyond version two of SimpleScreen CRC to further increase sensitivity for advanced lesions.

Dr. Aasma Shaukat and her research team plan to submit the updated SimpleScreen CRC test to the FDA for regulatory approval.

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition